Glenmark Pharma share price has plunged 3% and is presently trading at Rs 1,661.0.
Meanwhile, the BSE HEALTHCARE index is at 43,061.3 (down 0.8%).
Among the top losers in the BSE HEALTHCARE index today are Dr. Reddys (down 3.4%) and POLY MEDICURE (down 3.0%).
CAPLIN POINT (up 3.6%) and MAX HEALTHCARE INSTITUTE (up 2.2%) are among the top gainers today.
Over the last one year, Glenmark Pharma has moved up from Rs 751.5 to Rs 1,661.0, registering a gain of Rs 909.5 (up 121.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,318.2 to 43,061.3, registering a gain of 57.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 224.6%), Glenmark Pharma (up 121.0%) and SUVEN PHARMACEUTICALS (up 118.8%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 79,870.7 (down 0.2%).
The top losers among the BSE Sensex today are Tata Motors (down 4.6%) and Indusind Bank (down 2.6%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.
In the meantime, NSE Nifty is at 24,292.5 (down 0.2%). Tata Motors and Dr. Reddys are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,049.1 to 79,870.7, registering a gain of 15,821.6 points (up 24.7%).
Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.
For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.
The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.7.
Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!